Burden of potentially avoidable anticoagulant-associated hemorrhagic and thromobembolic events in the elderly

Chest

Volumn 131, Issue 5, 2007, Pages 1508-1515

  Van Walraven, Carl ^a   Oake, Natalie ^a   Wells, Philip S ^a   Forster, Alan J ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Anticoagulation; Biostatistics; Bleeding; Deep venous thrombosis; Gastroenterology; Pulmonary embolism

Indexed keywords

ANTICOAGULANT AGENT;

AGED; ANTICOAGULATION; ARTICLE; BLEEDING DISORDER; BRAIN HEMORRHAGE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG CONTROL; DRUG EXPOSURE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STROKE; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

EID: 34248584516     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.06-2628     Document Type: Article

References (38)

1. van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest 2006; 129:1155-1166
2. Tangelder MJD, Algra A, Lawson JA, et al. Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. J Vasc Surg 2001; 33:522-527
3. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333:11-17
4. Veeger NJ, Piersma-Wichers M, Tijssen JG, et al. Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome: a retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol 2005; 128:51.3-519
5. Palareti G, Manotti C, DAngelo A, et al. Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study: iSCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy). Thromb Haemost 1997; 78:1438-1443
6. Oden A, Fahlen M. Oral anticoagulation and risk of death: a medical record linkage study. BMJ 2002; 325:1073-1075
7. Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42:857-865
8. European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995; 333:5-10
9. Azar AJ, Cannegieter SC, Deckers JW, et al. Optimal intensity of oral anticoagulant therapy after myocardial infarction. J Am Coll Cardiol 1996; 27:1349-1355
10. Casais P, Luceros AS, Meschengieser S, et al. Bleeding risk factors in chronic oral anticoagulation with acenocoumarol. Am J Hematol 2000; 63:192-196
11. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT); Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-428
12. Wilson SJ-A, Wells PS, Kovacs MJ, et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. Can Med Assoc J 2003; 169:293-298
13. Samsa GP, Matchar DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 2000; 160:967-973
14. Witt DM, Sadler MA, Shanahan RL, et al. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 2005; 127:1515-1522
15. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, et al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006; 367:404-411
16. Hanley JA. A heuristic approach to the formulas for population attributable fraction. J Epidemiol Community Health 2001; 55:508-514
17. Johnsen SP, Sorensen HT, Mellemkjoer L, et al. Hospitalisation for upper gastrointestinal bleeding associated with use of oral anticoagulants. Thromb Haemost 2001; 86:563-568
18. Rockhill B, Newman B, Weinberg C, et al. Use and misuse of population attributable fractions. Am J Public Health 1998; 88:15-19
19. Last JM. A dictionary of epidemiology. New York, NY: Oxford University Press, 1995
20. Rowland D. Population growth and decline: demographic methods and concepts. London, UK: Oxford University Press, 2003; 45-75
21. van Walraven C, Raymond M. A population-based study of repeat laboratory testing. Clin Chem 2003; 49:1997-2005
22. Tu JV, Naylor CD, Austin P. Temporal changes in the outcomes of acute myocardial infarction in Ontario, 1992-1996. Can Med Assoc J 1999; 161:1257-1261
23. Ontario Ministry of Health and Long Term Care. Ontario Drug Benefit Formulary: Part 1. Introduction. 2003; I:14
24. Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69:236-239
25. Fleiss JL, Levin B, Paik MC. Poisson regression. In: Statistical methods for rates and proportions. Hoboken, NJ: John Wiley & Sons, 2003; 340-372
26. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(suppl):204S-233S
27. Salem DN, Stein PD, Al Ahmad A, et al. Antithrombotic therapy in valvular heart disease-native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(suppl):457S-482S
28. Lip GY, Kamath S, Jafri M, et al. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation Project. Stroke 2002; 33:238-242
29. Walter SD, Walter SD. Calculation of attributable risks from epidemiological data. Int J Epidemiol 1978; 7:175-182
30. Torn M, Algra A, Rosendaal FR. Oral anticoagulation for cerebral ischemia of arterial origin: high initial bleeding risk. Neurology 2001; 57:1993-1999
31. Tangelder MJ, Algra A, Lawson JA, et al. Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery: Dutch BOA Study Group. J Vasc Surg 2001; 33:522-527
32. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349:1019-1026
33. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352:1305-1316
34. van Walraven C, Austin PC, Oake N, et al. The effect of hospitalization on oral anticoagulation control: a population-based study. Thromb Res 2006 (July 14, E-pub ahead of print)
35. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351:1285-1295
36. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17:2034-2047
37. Arnason T, Wells PS, van Walraven C, et al. Accuracy of coding for possible warfarin complications in hospital discharge abstracts. Thromb Res 2006; 118:253-262
38. van Walraven C, Mamdani M, Cohn A, et al. Risk of subsequent thromboembolism for patients with pre-eclampsia. BMJ 2003; 326:791-792